Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.

Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, Greenhalf W, Shaw V, Michalski CW, Friess H, Neoptolemos JP, Costello E.

Br J Cancer. 2013 May 14;108(9):1846-53. doi: 10.1038/bjc.2013.150. Epub 2013 Apr 11.

2.

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.

BMC Cancer. 2013 Sep 3;13:404. doi: 10.1186/1471-2407-13-404.

3.

Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.

O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A, Zaikin A, Smith RC, Jacobs IJ, Menon U, Costello E, Pereira SP, Timms JF.

Clin Cancer Res. 2015 Feb 1;21(3):622-31. doi: 10.1158/1078-0432.CCR-14-0365. Epub 2014 Jun 17.

4.

CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F.

Am J Surg. 2009 Sep;198(3):333-9. doi: 10.1016/j.amjsurg.2008.12.031. Epub 2009 Apr 17.

PMID:
19375064
5.

Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.

Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E.

Mol Cancer. 2014 May 20;13:114. doi: 10.1186/1476-4598-13-114.

6.

Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.

Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, Blasutig IM.

Clin Cancer Res. 2014 Nov 15;20(22):5787-95. doi: 10.1158/1078-0432.CCR-14-0289. Epub 2014 Sep 19.

7.

CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.

Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N.

J Surg Oncol. 2007 Feb 1;95(2):142-7.

PMID:
17262731
9.

Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients.

Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX.

BMC Cancer. 2008 Aug 16;8:241. doi: 10.1186/1471-2407-8-241.

10.

Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.

Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY.

Cancer Sci. 2012 Sep;103(9):1714-21. doi: 10.1111/j.1349-7006.2012.02358.x. Epub 2012 Jul 30.

11.

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.

Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W.

BMC Cancer. 2014 Aug 8;14:578. doi: 10.1186/1471-2407-14-578.

12.

Serum biomarker panels for the detection of pancreatic cancer.

Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE.

Clin Cancer Res. 2011 Feb 15;17(4):805-16. doi: 10.1158/1078-0432.CCR-10-0248.

13.

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.

Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.

Clin Cancer Res. 2006 Jan 15;12(2):442-6.

14.

Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.

Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.

Int J Pancreatol. 1994 Jun;15(3):171-7.

PMID:
7930777
15.

Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.

Joergensen MT, Heegaard NH, Schaffalitzky de Muckadell OB.

Pancreas. 2010 Mar;39(2):243-7. doi: 10.1097/MPA.0b013e3181bae8ab.

PMID:
19820423
16.

Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.

Mann DV, Edwards R, Ho S, Lau WY, Glazer G.

Eur J Surg Oncol. 2000 Aug;26(5):474-9.

PMID:
11016469
17.

Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.

Ferri MJ, Saez M, Figueras J, Fort E, Sabat M, López-Ben S, de Llorens R, Aleixandre RN, Peracaula R.

PLoS One. 2016 Jan 25;11(1):e0147214. doi: 10.1371/journal.pone.0147214. eCollection 2016.

18.

Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art.

Plebani M, Basso D, Panozzo MP, Fogar P, Del Favero G, Naccarato R.

Int J Biol Markers. 1995 Oct-Dec;10(4):189-99. Review.

PMID:
8750644
19.

[CA19-9 has no value as a tumor marker in obstructive jaundice].

Peterli R, Meyer-Wyss B, Herzog U, Tondelli P.

Schweiz Med Wochenschr. 1999 Jan 23;129(3):77-9. Review. German.

PMID:
10065510
20.

Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.

Parikh DA, Durbin-Johnson B, Urayama S.

J Gastrointest Cancer. 2014 Mar;45(1):74-9. doi: 10.1007/s12029-013-9563-x.

Items per page

Supplemental Content

Write to the Help Desk